Press / Medias

Health and Life Science deals

Sep 28, 2017

LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.

In the same category

Press / Medias

Bordeaux : un traitement prometteur contre l’obésité développé à base d’une...

Jun 16, 2021

more +
Press / Medias

Le pari gagnant du microbiome

May 24, 2021

more +
Press / Medias

In the clinic for March 4, 2021

Mar 4, 2021

more +

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions